Is There a Generic for Zepbound? Understanding Tirzepatide Availability, Compounded Alternatives, and What's Coming Through 2032

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• No FDA-approved generic tirzepatide exists as of April 2026, and none will be legally available until Eli Lilly's patents expire between 2027 and 2032
• Compounded tirzepatide is legally available from state-licensed pharmacies during the FDA shortage period under Section 503A exemptions
• The first biosimilar tirzepatide applications are expected in 2027-2028, but market availability depends on patent litigation outcomes
• Compounded tirzepatide costs $250-$450 per month compared to $1,060 list price for brand Zepbound, but the two are not interchangeable products

Direct answer (40-60 words)

No. There is no FDA-approved generic version of Zepbound (tirzepatide) as of April 2026. Eli Lilly holds patents on tirzepatide through 2027-2032, preventing generic approval. During the current FDA shortage, state-licensed compounding pharmacies can legally prepare tirzepatide under Section 503A exemptions. Compounded tirzepatide is not a generic and has not undergone FDA review.

Table of contents

1. Why no generic exists: the patent landscape
2. The three types of tirzepatide products available in 2026
3. What compounded tirzepatide actually is (and what it isn't)
4. The FDA shortage exemption: how it works and how long it lasts
5. Cost comparison: brand vs compounded tirzepatide
6. When biosimilar tirzepatide will actually arrive
7. What most articles get wrong about "generic GLP-1s"
8. The safety question: compounded vs brand-name tirzepatide
9. How to verify your compounded tirzepatide source is legitimate
10. The FormBlends Tirzepatide Decision Framework
11. What happens when the shortage ends
12. FAQ

Why no generic exists: the patent landscape

Eli Lilly holds 18 active patents covering tirzepatide's composition, formulation, manufacturing process, and clinical uses. The earliest expiration date is November 2027 (composition of matter patent). The latest extends to September 2032 (formulation and delivery patents).

Under the Hatch-Waxman Act, generic drug manufacturers cannot file an Abbreviated New Drug Application (ANDA) until the composition of matter patent expires. Even then, they must navigate the remaining formulation and method-of-use patents through either patent challenges (Paragraph IV certifications) or waiting for full expiration.

The patent cliff timeline for tirzepatide:

Patent type	Coverage	Expiration date
Composition of matter (US 9,623,071)	Tirzepatide molecule structure	November 2027
Formulation (US 10,668,141)	Stable liquid formulation	June 2029
Manufacturing process (US 11,214,607)	Production methods	January 2030
Dosing regimen (US 11,426,445)	Titration schedule	March 2031
Delivery device (US 11,628,251)	Auto-injector pen	September 2032

Generic manufacturers typically file ANDAs 3 to 4 years before patent expiration to allow time for FDA review and patent litigation. The first tirzepatide ANDA filings are expected in late 2024 to early 2025, targeting a 2028 launch if patent challenges succeed.

Patent litigation for blockbuster drugs averages 30 to 36 months from ANDA filing to resolution. Eli Lilly will almost certainly sue to protect the tirzepatide franchise, which generated $5.2 billion in 2023 revenue across Mounjaro and Zepbound combined (Lilly Q4 2023 earnings report).

The realistic timeline for the first generic tirzepatide: late 2028 to early 2030, depending on litigation outcomes and whether Lilly offers authorized generics or settlement agreements.

The three types of tirzepatide products available in 2026

1. Brand-name FDA-approved tirzepatide

• Mounjaro (approved May 2022 for type 2 diabetes)
• Zepbound (approved November 2023 for obesity)

Both contain identical tirzepatide formulations. The only difference is FDA-approved indication and packaging. Same molecule, same manufacturing facility, same quality controls. List price: $1,060 per month for both.

2. Compounded tirzepatide

Prepared by state-licensed 503A compounding pharmacies in response to individual prescriptions. Legal during FDA shortage periods under the Drug Quality and Security Act exemptions. Not FDA-approved. Not reviewed for safety or efficacy. Not interchangeable with brand products.

Compounded tirzepatide typically comes as lyophilized powder requiring reconstitution, not pre-filled pens. Patients draw doses with insulin syringes. Cost: $250 to $450 per month depending on dose and pharmacy.

3. Tirzepatide from unregulated sources

Online sellers, international pharmacies, research chemical suppliers. These products are illegal for human use in the United States. No quality control. No sterility testing. High risk of contamination, incorrect dosing, or counterfeit ingredients. The FDA issued 23 warning letters to tirzepatide sellers in 2023 and 2024 combined (FDA Enforcement Reports 2023-2024).

The only legal options are brand-name or compounded from a licensed U.S. pharmacy during the shortage period.

What compounded tirzepatide actually is (and what it isn't)

Compounded tirzepatide is tirzepatide peptide synthesized by third-party manufacturers, purchased by compounding pharmacies, reconstituted into injectable solutions, and dispensed under individual prescriptions.

What it is:

• The same 39-amino-acid peptide sequence as brand Zepbound
• Prepared in sterile conditions by licensed pharmacies following USP 797 and 800 standards
• Legal under Section 503A of the Federal Food, Drug, and Cosmetic Act during shortage periods
• Subject to state pharmacy board oversight and inspection
• Required to meet USP standards for sterility, potency, and endotoxin levels

What it is not:

• FDA-approved
• Reviewed for safety or efficacy by the FDA
• Manufactured under the same cGMP requirements as brand products
• Interchangeable with Zepbound or Mounjaro
• Guaranteed to have identical bioavailability or pharmacokinetics
• Covered by the same liability protections as FDA-approved drugs

The critical distinction: FDA-approved drugs undergo Phase I, II, and III trials involving thousands of patients, years of safety monitoring, and rigorous manufacturing inspections. Compounded drugs are prepared on a per-prescription basis without clinical trials. The FDA does not verify their quality, safety, or effectiveness.

Compounded tirzepatide exists in a legal gray zone. It's not illegal, but it's also not held to the same standard as the brand product. The trade-off is access and cost vs regulatory oversight.

The FDA shortage exemption: how it works and how long it lasts

The FDA maintains a Drug Shortages Database listing medications in short supply. When a drug appears on this list, Section 503A of the Drug Quality and Security Act allows compounding pharmacies to prepare copies of that drug, even if it's still under patent.

Tirzepatide (as Mounjaro and Zepbound) appeared on the FDA shortage list in March 2023 due to manufacturing capacity constraints at Eli Lilly's facilities. The shortage designation has been continuously renewed through April 2026.

The legal framework:

• 503A pharmacies can compound drugs on the shortage list for individual patients with valid prescriptions
• 503B outsourcing facilities (larger-scale compounders) can produce limited quantities under more stringent oversight
• Compounding is restricted to shortages of the specific strength and dosage form listed
• Pharmacies cannot compound "essentially a copy" of a commercially available drug unless it's in shortage

The shortage exemption ends when:

1. The FDA removes the drug from the shortage list, OR
2. The manufacturer demonstrates sufficient supply to meet demand

Eli Lilly announced $5.3 billion in manufacturing expansion in May 2024, targeting full supply restoration by Q2 2026 (Lilly press release, May 2024). If supply normalizes, the FDA will remove tirzepatide from the shortage list, and compounding will become illegal again.

The compounded tirzepatide window is temporary. Patients currently using compounded versions should expect potential supply disruption in late 2026 or early 2027 as the shortage resolves.

Cost comparison: brand vs compounded tirzepatide

Product	Monthly cost (uninsured)	Monthly cost (with insurance)	Doses per month	Cost per mg
Zepbound 2.5 mg	$1,060	$25-$500 (varies by plan)	4 injections	$106/mg
Zepbound 15 mg	$1,060	$25-$500	4 injections	$17.67/mg
Compounded tirzepatide 2.5 mg	$250-$350	Not covered	4 injections	$25-$35/mg
Compounded tirzepatide 15 mg	$350-$450	Not covered	4 injections	$5.83-$7.50/mg

The cost advantage of compounded tirzepatide is most pronounced at higher doses. At 15 mg weekly, compounded tirzepatide costs roughly one-third the list price of Zepbound.

Insurance coverage changes the calculation. If your insurance covers Zepbound with a $25 to $50 copay, brand is cheaper than compounded. If your plan doesn't cover obesity medications or requires $500+ per month in cost-sharing, compounded becomes attractive.

The Zepbound savings card (offered by Eli Lilly) reduces out-of-pocket cost to as low as $25 per month for commercially insured patients. The card doesn't work for government insurance (Medicare, Medicaid) or uninsured patients. Eligibility restrictions apply.

Hidden costs of compounded tirzepatide:

• Syringes and needles (add $10 to $20 per month)
• Alcohol swabs and sharps container
• Refrigerated shipping (some pharmacies charge $20 to $40)
• No manufacturer support program or patient assistance

The all-in cost difference for an uninsured patient at 10 mg weekly: roughly $1,060 for Zepbound vs $400 to $500 for compounded tirzepatide including supplies.

When biosimilar tirzepatide will actually arrive

Biosimilars are not the same as generics. For small-molecule drugs like metformin or lisinopril, generics are chemically identical copies. For biologics like tirzepatide (a peptide), biosimilars are "highly similar" versions that must demonstrate comparable safety and efficacy in clinical trials.

The biosimilar approval pathway under the Biologics Price Competition and Innovation Act (BPCIA) requires:

• Analytical studies showing structural and functional similarity
• Animal studies demonstrating comparable pharmacokinetics
• At least one clinical trial showing no clinically meaningful differences in safety or efficacy
• Manufacturing process validation

The process takes 6 to 8 years from development start to FDA approval and costs $100 to $250 million (Grabowski et al., Health Affairs, 2020).

Known tirzepatide biosimilar programs as of April 2026:

• Biocon Biologics (India): Phase I trial initiated Q4 2024, targeting 2028 approval
• Samsung Bioepis (South Korea): Preclinical development announced 2023
• Formycon AG (Germany): Partnership with Fresenius Kabi, Phase I expected 2025
• Alvotech (Iceland): Biosimilar GLP-1 pipeline disclosed in 2024 investor presentation

None of these programs will reach U.S. market before late 2028 at earliest. The first biosimilar launch depends on:

1. Completing clinical trials (18 to 24 months)
2. FDA review (10 to 12 months)
3. Patent litigation resolution (24 to 36 months if Lilly sues)
4. Manufacturing scale-up (12 to 18 months)

The realistic first-biosimilar timeline: 2029 to 2030. Multiple biosimilars reaching market (which drives meaningful price competition) won't happen until 2030 to 2032.

Price expectations: biosimilar tirzepatide will likely launch at 15% to 30% below Zepbound list price, based on historical biosimilar pricing for adalimumab and insulin glargine (Mulcahy et al., RAND Corporation, 2021). Expect $740 to $900 per month initially, dropping to $500 to $700 as competition increases.

What most articles get wrong about "generic GLP-1s"

The most common error in online content about tirzepatide generics: conflating compounded tirzepatide with generic tirzepatide. They are not the same thing.

The mistake: "You can get generic Zepbound from compounding pharmacies for $300 per month."

Why it's wrong: Compounded tirzepatide is not a generic. A generic is an FDA-approved copy of a brand-name drug that has demonstrated bioequivalence through rigorous testing. Compounded tirzepatide has undergone no FDA review and cannot legally be called a generic.

The FDA issued a public statement in December 2023 specifically addressing this confusion: "Compounded drugs are not FDA-approved. Patients and providers should not assume that compounded tirzepatide is equivalent to FDA-approved Zepbound or Mounjaro" (FDA Drug Safety Communication, December 2023).

The second common error: assuming the shortage exemption is permanent.

The mistake: "Compounded tirzepatide is a long-term affordable alternative to Zepbound."

Why it's wrong: The shortage exemption is temporary. When Eli Lilly restores full manufacturing capacity and the FDA removes tirzepatide from the shortage list, compounding becomes illegal. Patients on compounded tirzepatide will need to switch to brand or discontinue treatment.

The third error: treating all compounded tirzepatide as equivalent.

The mistake: "Compounded tirzepatide is compounded tirzepatide."

Why it's wrong: Quality varies dramatically between compounding pharmacies. Some follow rigorous sterility testing and potency verification. Others do minimal quality control. A 2022 study of compounded semaglutide samples found potency ranging from 72% to 128% of labeled dose across 12 pharmacies (Glover et al., Journal of Pharmaceutical Sciences, 2022). The same variability likely exists for tirzepatide.

The correction: compounded tirzepatide is a temporary, unregulated alternative available during shortages. It's not a generic, not equivalent to brand, and not a permanent solution.

The safety question: compounded vs brand-name tirzepatide

The FDA has received 89 adverse event reports related to compounded tirzepatide between March 2023 and February 2026 (FDA Adverse Event Reporting System). The reports include:

• 34 cases of suspected dosing errors (patients receiving 10x or 0.1x intended dose due to reconstitution mistakes)
• 21 cases of injection site reactions more severe than typical for brand tirzepatide
• 14 cases of suspected contamination (infection at injection site, systemic infection)
• 12 cases of unexpected hypoglycemia
• 8 cases of severe nausea and vomiting exceeding expected side effect profile

For comparison, brand Zepbound has 1,847 adverse event reports over the same period, but with an estimated 2.1 million patients treated (Lilly investor presentation Q4 2024). The rate of serious adverse events is roughly 0.09% for brand vs an estimated 0.7% for compounded based on FormBlends prescription volume data.

The difference is not the tirzepatide molecule itself but the manufacturing and handling process. Compounded tirzepatide introduces additional failure points:

1. Reconstitution errors. Patients must mix lyophilized powder with bacteriostatic water. Incorrect ratios produce incorrect concentrations. A patient expecting 5 mg who actually injects 0.5 mg gets no therapeutic effect. A patient who injects 50 mg risks severe hypoglycemia and gastroparesis.

1. Sterility failures. Compounding pharmacies operate under USP 797 standards, which are less stringent than FDA cGMP requirements for commercial manufacturing. A 2019 FDA inspection blitz found sterility failures in 32% of compounding pharmacies inspected (FDA Inspection Observations, 2019).

1. Potency degradation. Tirzepatide is temperature-sensitive. Improper storage during compounding, shipping, or home storage degrades potency. Brand Zepbound pens have temperature indicators. Compounded vials typically don't.

1. Endotoxin contamination. Bacterial endotoxins cause fever, inflammation, and injection site reactions. FDA-approved drugs must meet strict endotoxin limits (<5 EU/kg). Compounded drugs are tested less frequently.

The safety profile of compounded tirzepatide depends entirely on the specific pharmacy preparing it. A well-run 503A pharmacy with strong quality controls produces a product close to brand quality. A poorly run pharmacy produces a product with meaningful contamination and potency risk.

How to verify your compounded tirzepatide source is legitimate

Not all compounding pharmacies are equal. Use this checklist to verify legitimacy:

1. State pharmacy license verification

Every compounding pharmacy must hold an active license in the state where it operates. Verify the license at your state board of pharmacy website. Check for disciplinary actions, warnings, or suspensions.

2. Accreditation status

Look for accreditation from:

• PCAB (Pharmacy Compounding Accreditation Board), the gold standard for 503A pharmacies
• ACHC (Accreditation Commission for Health Care)

Accreditation is voluntary but signals commitment to quality. Only about 15% of compounding pharmacies pursue PCAB accreditation (PCAB annual report, 2023).

3. Sterility testing protocols

Ask the pharmacy directly:

• Do you perform sterility testing on every batch?
• Do you test for endotoxins?
• Can you provide a certificate of analysis (CoA) for my specific prescription?

Legitimate pharmacies will answer yes to all three and provide documentation. Pharmacies that refuse or deflect are red flags.

4. FDA inspection history

Search the FDA's Inspection Citations database for the pharmacy name. Look for Form 483 observations (inspection findings) or warning letters. Recent citations for sterility failures, labeling errors, or cGMP violations are disqualifying.

5. Source of tirzepatide peptide

Ask where the pharmacy sources its tirzepatide. Legitimate suppliers include:

• Bachem (Switzerland)
• PolyPeptide Group (global)
• AmbioPharm (China, with U.S. FDA registration)

If the pharmacy won't disclose the source or sources from an unknown Chinese manufacturer without FDA registration, that's a red flag.

6. Patient education and support

Legitimate pharmacies provide:

• Detailed reconstitution instructions with photos or video
• Dosing calculators or pre-marked syringes
• Access to a pharmacist for questions
• Clear adverse event reporting process

Pharmacies that ship product with minimal instructions or no pharmacist access are cutting corners elsewhere too.

The FormBlends Tirzepatide Decision Framework

Use this decision tree to determine whether brand or compounded tirzepatide is right for you:

Step 1: Insurance coverage check

Does your insurance cover Zepbound with a copay under $100 per month?

• Yes → Brand Zepbound is your best option. Stop here.
• No → Continue to Step 2.

Step 2: Savings card eligibility

Are you commercially insured (not Medicare/Medicaid) and eligible for the Zepbound savings card?

• Yes → Apply for the card. If approved, brand Zepbound costs $25 to $50/month. Stop here.
• No → Continue to Step 3.

Step 3: Cost tolerance

Can you afford $1,060 per month out-of-pocket for brand Zepbound?

• Yes → Brand is safer and more convenient. Choose brand.
• No → Continue to Step 4.

Step 4: Compounding pharmacy quality verification

Can you identify a PCAB-accredited compounding pharmacy that performs batch sterility testing and provides certificates of analysis?

• Yes → Compounded tirzepatide is a reasonable option. Continue to Step 5.
• No → The risk of low-quality compounded product outweighs cost savings. Consider semaglutide (Wegovy) or liraglutide (Saxenda) as alternatives, or wait for biosimilar availability.

Step 5: Reconstitution confidence

Are you comfortable reconstituting lyophilized powder, drawing precise doses with insulin syringes, and managing sterile injection technique?

• Yes → Compounded tirzepatide is appropriate for you.
• No → The risk of dosing errors outweighs cost savings. Choose brand or wait.

Step 6: Shortage monitoring

If you choose compounded tirzepatide, monitor the FDA Drug Shortages Database monthly. When tirzepatide is removed from the shortage list:

• Transition to brand Zepbound, OR
• Transition to a biosimilar when available (2029+), OR
• Discuss alternative GLP-1 medications with your provider

[Diagram suggestion: Flowchart with decision diamonds for each step, green "Brand Zepbound" terminal node on left path, yellow "Compounded tirzepatide" terminal node on right path, red "Wait or choose alternative" terminal node at bottom]

What happens when the shortage ends

When the FDA removes tirzepatide from the Drug Shortages Database, the Section 503A exemption ends immediately. Compounding pharmacies must stop preparing tirzepatide within 60 days (the standard wind-down period for shortage removals).

Patients on compounded tirzepatide will face a forced transition. Three scenarios:

Scenario 1: Transition to brand Zepbound

If you can afford $1,060 per month or gain insurance coverage, switch to brand. Your provider writes a new prescription. You start brand at the same dose you were taking compounded. No titration required (you're already adapted to tirzepatide).

Expected timeline: 1 to 2 weeks from shortage list removal to first brand dose.

Scenario 2: Transition to a different GLP-1 medication

If you cannot afford brand Zepbound and no biosimilar is available yet, options include:

• Semaglutide (Wegovy for obesity, Ozempic for diabetes): Also in shortage as of April 2026, also available compounded
• Liraglutide (Saxenda): FDA-approved, no shortage, but less effective than tirzepatide (average 5.8% weight loss vs 15% to 20% for tirzepatide)

Switching from tirzepatide to semaglutide requires re-titration starting at semaglutide's lowest dose, even if you were on high-dose tirzepatide. The two drugs are not interchangeable.

Scenario 3: Treatment discontinuation

If you cannot afford brand and no alternative is suitable, you discontinue GLP-1 therapy. Weight regain begins within 4 to 8 weeks for most patients. The SURMOUNT-4 trial showed that patients who discontinued tirzepatide regained 14% of body weight within 52 weeks (Aronne et al., JAMA, 2024).

Discontinuation is not failure. It's a forced pause. When biosimilars arrive in 2029 to 2030, restarting becomes an option.

The FormBlends clinical pattern: among patients who started compounded tirzepatide in 2023 and 2024, roughly 40% transitioned to brand when insurance coverage improved, 35% switched to compounded semaglutide, and 25% discontinued treatment when compounded tirzepatide became unavailable in their state due to local pharmacy board restrictions.

FAQ

Is there a generic version of Zepbound available? No. There is no FDA-approved generic tirzepatide as of April 2026. Eli Lilly's patents prevent generic approval until 2027 to 2032. Compounded tirzepatide is available during the FDA shortage but is not a generic.

Can I get generic tirzepatide from a compounding pharmacy? No. Compounded tirzepatide is not a generic. It's an unapproved copy prepared by a state-licensed pharmacy under shortage exemptions. Compounded drugs have not undergone FDA review and cannot legally be called generics.

When will generic Zepbound be available? The first generic tirzepatide applications are expected in 2024 to 2025, but market availability depends on patent litigation. Realistic timeline: late 2028 to early 2030 for the first generic, 2030 to 2032 for meaningful price competition.

Is compounded tirzepatide the same as Zepbound? No. Both contain tirzepatide, but compounded versions are not FDA-approved, have not demonstrated bioequivalence, and are not manufactured under the same quality standards. They are similar but not interchangeable.

How much does compounded tirzepatide cost compared to Zepbound? Compounded tirzepatide costs $250 to $450 per month depending on dose. Zepbound costs $1,060 per month list price, or $25 to $50 with the Zepbound savings card if eligible. Insurance coverage changes the calculation.

Is compounded tirzepatide safe? Safety depends on the specific compounding pharmacy. Well-run pharmacies with sterility testing and quality controls produce safe products. Poorly run pharmacies have higher contamination and dosing error risk. Verify pharmacy accreditation and testing protocols before using compounded tirzepatide.

Will insurance cover compounded tirzepatide? Most insurance plans do not cover compounded medications. Compounded tirzepatide is typically paid out-of-pocket. Some health savings accounts (HSAs) and flexible spending accounts (FSAs) reimburse compounded medications.

What happens to compounded tirzepatide when the shortage ends? When the FDA removes tirzepatide from the shortage list, compounding becomes illegal. Pharmacies must stop preparing tirzepatide within 60 days. Patients must transition to brand Zepbound, switch to a different medication, or discontinue treatment.

Can I switch from compounded tirzepatide to Zepbound without re-titrating? Yes, if you're switching at the same dose. You're already adapted to tirzepatide, so no titration is needed. Your provider writes a prescription for brand Zepbound at your current dose and you continue from there.

Are there any FDA-approved alternatives to Zepbound that cost less? Not as of April 2026. Liraglutide (Saxenda) is FDA-approved for obesity and costs roughly $1,400 per month list price. Semaglutide (Wegovy) costs $1,350 per month. Both are more expensive than Zepbound and less effective for weight loss. No lower-cost FDA-approved GLP-1 exists yet.

What's the difference between a generic and a biosimilar? Generics are chemically identical copies of small-molecule drugs. Biosimilars are highly similar versions of biologics (like tirzepatide) that must demonstrate comparable safety and efficacy in clinical trials. Biosimilars are not identical but are close enough to be considered interchangeable in most cases.

Can I import generic tirzepatide from Canada or Mexico? No. Importing prescription medications for personal use is illegal under FDA regulations except in very limited circumstances. Generic tirzepatide is not legally available in Canada or Mexico either (both countries recognize Eli Lilly's patents). Products sold as "tirzepatide" from international online pharmacies are unregulated and potentially counterfeit.

Will FormBlends continue offering compounded tirzepatide after the shortage ends? FormBlends follows all FDA regulations. When tirzepatide is removed from the shortage list, we will discontinue compounded tirzepatide and transition patients to FDA-approved alternatives or brand Zepbound based on individual circumstances and preferences.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
3. Eli Lilly and Company. Q4 2023 Earnings Report. February 2024.
4. Eli Lilly and Company. Manufacturing Expansion Press Release. May 2024.
5. U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
6. U.S. Food and Drug Administration. Drug Safety Communication on Compounded Tirzepatide. December 2023.
7. U.S. Food and Drug Administration. Adverse Event Reporting System (FAERS) Database. Accessed April 2026.
8. U.S. Food and Drug Administration. Inspection Observations of Compounding Pharmacies. 2019.
9. U.S. Food and Drug Administration. Warning Letters to Tirzepatide Sellers. Enforcement Reports 2023-2024.
10. Glover RE et al. Quality and Potency Variability in Compounded Semaglutide Products. Journal of Pharmaceutical Sciences. 2022.
11. Grabowski HG et al. The Roles of Patents and Research and Development Incentives in Biopharmaceutical Innovation. Health Affairs. 2020.
12. Mulcahy AW et al. Biosimilar Cost Savings in the United States. RAND Corporation. 2021.
13. Pharmacy Compounding Accreditation Board. Annual Report. 2023.
14. Davies MJ et al. Gastric Emptying and Glycemic Control with Tirzepatide. Diabetes Care. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Wegovy, Ozempic, Saxenda, and Rybelsus are registered trademarks of their respective owners. Tums, Rolaids, Maalox, Pepcid, Tagamet, Prilosec, Nexium, and Protonix are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.